KemPharm is a biopharmaceutical company focused on the discovery and development of new, safer therapies in the areas of pain, ADHD, and other CNS diseases. Its primary efforts include the development of safer, abuse resistant opioid pain relievers. KemPharm’s drug discovery and development platform is based on its proprietary Ligand Activated Therapy (LAT) approach. The Company uses its patent-applied technology to improve existing drugs and shorten the development timeline while still maintaining a strong intellectual property position within each therapeutic area.

Employee Rating

0More
TypePublic
HQKissimmee, US
Founded2006
Size (employees)32 (est)
Websitekempharm.com
KemPharm was founded in 2006 and is headquartered in Kissimmee, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at KemPharm

Travis C. Mickle

Travis C. Mickle

President, Chief Executive Officer and Chairman of the Board; Co-Founder
Christal M.m. Mickle

Christal M.m. Mickle

Vice President, Operations and Product Development; Co-Founder
Andrew Barrett

Andrew Barrett

Vice President, Scientific Affairs
Rene A. Braeckman

Rene A. Braeckman

Vice President, Clinical Development
Christopher M. Lauderback

Christopher M. Lauderback

Vice President, Manufacturing
Show more

KemPharm Office Locations

KemPharm has an office in Kissimmee
Kissimmee, (HQ)
1180 Celebration Blvd
Show all (1)
Report incorrect company information

KemPharm Financials and Metrics

KemPharm Revenue

USD

Net income (Q2, 2018)

(10.0m)

EBIT (Q2, 2018)

(13.9m)

Market capitalization (4-Dec-2018)

69.0m

Closing stock price (4-Dec-2018)

2.6

Cash (30-Jun-2018)

16.5m
KemPharm's current market capitalization is $69 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

8.9m14.0m12.8m

R&D expense

13.9m20.5m20.6m

Operating expense total

22.8m37.5m33.4m

EBIT

(22.8m)(37.5m)(33.4m)
Quarterly
USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

3.2m3.7m4.3m3.1m3.3m3.3m3.1m3.4m

R&D expense

2.8m3.2m5.0m4.3m4.1m6.3m11.6m10.5m

Operating expense total

6.0m7.0m9.3m10.4m7.4m9.6m14.8m13.9m

EBIT

(6.0m)(7.0m)(9.3m)(10.4m)(7.4m)(9.6m)(14.8m)(13.9m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

32.3m16.8m10.9m

Inventories

2.8m489.0k

Current Assets

54.1m74.4m47.0m

PP&E

403.0k2.0m2.0m
Quarterly
USDQ2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

64.2m77.3m27.5m20.8m12.9m7.8m8.8m16.5m

Inventories

1.4m

Current Assets

64.8m111.4m84.6m65.3m63.0m50.2m39.1m30.9m

PP&E

352.0k443.0k1.1m1.5m2.2m2.1m1.9m1.8m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(54.7m)(16.5m)(43.4m)

Depreciation and Amortization

84.0k175.0k336.0k

Inventories

(1.2m)(15.9m)

Accounts Payable

1.3m1.1m(801.0k)
Quarterly
USDQ1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

1.4m

Accounts Payable

4.0m4.9m4.2m5.4m5.6m4.6m6.3m6.4m
USDY, 2018

Financial Leverage

-0.4 x
Show all financial metrics
Report incorrect company information

KemPharm Online and Social Media Presence

Embed Graph
Report incorrect company information

KemPharm News and Updates

KemPharm to Webcast Live at VirtualInvestorConferences.com on December 6th

CELEBRATION, Fla., Dec. 3, 2018 /PRNewswire/ -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its President and CEO, Travis Mickle, Ph.D., will present live at...

Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings

Shares of Aytu BioScience Inc. plummeted 33% and of KemPharm Inc. plunged 32% Friday, to pace the Nasdaq's decliners, as both specialty pharmaceutical companies announced relatively large public share offerings that priced at deep discounts. KemPharm offered 8.33 million shares, representing 52% o…

KemPharm Announces Proposed Public Offering of Common Stock

CORALVILLE, Iowa, Oct. 04, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.  A…

KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape

Event to be Webcast Live on Thursday, October 11, 2018, at 8:30 a.m. ET

KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference

CORALVILLE, Iowa, Aug. 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C. Mickle, Ph.D., will present at the Canacc…
Show more
Report incorrect company information

KemPharm Blogs

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder Content Import Tue, 11/13/2018 - 07:33 KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder November 13, 2018 at…

KemPharm, Inc. Reports Third Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01 efficacy and safety trial in children with attention deficit hyperactivity disorder (ADHD) Announced positive topline results f…

KemPharm to Report Third Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 8, 2018, 4:30 p.m. ET Coralville, IA – November 1, 2018 –KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced …

KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®

Partnership with KVK, One of the Largest Manufacturers of Controlled Substances in the U.S., Opens the Door for Commercial Launch of APADAZ with PBMs and MCOs KemPharm to Host a Conference Call Today, Tuesday, October 30, 2018 at 4:30 p.m. ET to Discuss the Collaboration Highlights: KemPharm to rece…

KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®

Partnership with KVK, One of the Largest Manufacturers of Controlled Substances in the U.S., Opens the Door for Commercial Launch of APADAZ with PBMs and MCOs KemPharm to Host a Conference Call Today, Tuesday, October 30, 2018 at 4:30 p.m. ET to Discuss the Collaboration Highlights: KemPharm to

KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

Coralville, IA – October 24, 2018 –KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced the presentation of posters from two human abuse potential (HAP) trials for its KP415 prodrug candidate to treat atten…
Show more

KemPharm Company Life and Culture

Report incorrect company information

KemPharm Frequently Asked Questions

  • When was KemPharm founded?

    KemPharm was founded in 2006.

  • Who are KemPharm key executives?

    KemPharm's key executives are Travis C. Mickle, Christal M.m. Mickle and Andrew Barrett.

  • How many employees does KemPharm have?

    KemPharm has 32 employees.

  • Who are KemPharm competitors?

    Competitors of KemPharm include Adaptive Biotechnologies, F-star Biotechnology and Spring Bank Pharmaceuticals.

  • Where is KemPharm headquarters?

    KemPharm headquarters is located at 1180 Celebration Blvd, Kissimmee.

  • Where are KemPharm offices?

    KemPharm has an office in Kissimmee.

  • How many offices does KemPharm have?

    KemPharm has 1 office.